Delcath Is On Schedule For A Monster 2025: A Platform Valuation Awaits

ALIOUI Mohammed Elamine/iStock via Getty Images Snowball Effect Just Getting Started When I wrote my bullish Delcath (NASDAQ:DCTH) article in November 2023 there was a lot of investor angst heading into the HEPZATO KIT launch in Q1 2024. It had received FDA approval in August 2023, but until sales start coming in, medical device stocks can move rapidly in either direction. Medical device stock volatility is the highest prior to approvals. Following approvals, it declines but is still elevated. The next step ...